Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE CLL/SLL Study: Early vs Delayed Venetoclax and Obinutuzumab in High-Risk CLL/SLL
NCT04269902Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2021
- Primary completion
- Oct 2028
- Countries
- 2
01
Overview
A Phase 3 trial of venetoclax, obinutuzumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by National Cancer Institute. Started Mar 2021; status: recruiting.
02
Drugs
venetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04269902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269902.